Search results
Results from the WOW.Com Content Network
SK-OV-3 (also known as SKOV-3; SK.OV.3; SKOV3; Skov3 and SKO3) is an ovarian cancer cell line derived from the ascites of a 64-year-old Caucasian female with an ovarian serous cystadenocarcinoma. [1] The SK-OV-3 cell line is also hypodiploid, with a modal number of chromosomes of 43 (range 42-45), occurring in 63.3% of cells.
Henrietta Lacks (born Loretta Pleasant; August 1, 1920 – October 4, 1951) [2] was an African-American woman [5] whose cancer cells are the source of the HeLa cell line, the first immortalized human cell line [B] and one of the most important cell lines in medical research. An immortalized cell line reproduces indefinitely under specific ...
The global search for a genetic basis for breast and ovarian cancer began in earnest in 1988. In 1990, at a meeting of the American Society of Human Genetics, a team of scientists led by Mary-Claire King, from the University of California, Berkeley announced the localization through linkage analysis of a gene associated with increased risk for breast cancer to the long arm of chromosome 17. [6]
In 2020, Cancer Cell made a number of changes to increase diversity and inclusion of underrepresented minorities in cancer research and oncology. In June 2020, the journal announced the new members of its advisory board (previously editorial board), which includes a higher representation of female scientists (>40%) and physicians (~50%) and ...
The implications of CASI extend to human health, especially in relation to sex-specific diseases. While hormonal influences have long been studied in diseases such as cancer (e.g., prostate cancer, ovarian cancer), CASI suggests that the cellular sex identity may also contribute to disease susceptibility and progression. [127] [128] [129]
According to research, most ovarian cancers start at the epithelial layer which is the lining of the ovary. Within this epithelial group ovarian clear-cell carcinoma makes up 5–10%. It was recognized as a separate category of ovarian cancer by the World Health Organization in 1973. Its incidence rate differs across various ethnic groups.
Serous ovarian cancer is the most common type of epithelial ovarian cancer and it accounts for about two-thirds of cases of epithelial ovarian cancer. [28] Low-grade serous carcinoma is less aggressive than high-grade serous carcinomas, though it does not typically respond well to chemotherapy or hormonal treatments. [ 28 ]
As ovarian cancer is rarely symptomatic until an advanced stage, [42] regular pre-emptive screening is a particularly important tool for avoiding the late stage at which most patients present. However, A 2011 US study found that transvaginal ultrasound and cancer marker CA125 screening did not reduce ovarian cancer mortality. [43]